SCALA aims to improve understanding of cancer survivorship by studying late effects and quality of life (QOL) across diverse populations. Using two large French cohorts (Constances and Gazel), the project compares cancer survivors to cancer-free individuals to assess impacts on sexual health, sleep, depression, and lifestyle. It also investigates how treatments and behaviors influence QOL. In 2026, updated QOL data (EORTC QLQ-SURV100) will be collected to identify and validate major late effects, evaluate their impact on functioning, and determine key risk factors. SCALA will provide a comprehensive mapping of late effects and inform targeted strategies to improve long-term outcomes and QOL for cancer survivors.
